TherapyTherapyТерапия2412-40362713-1823Bionika Media28876910.18565/therapy.2022.1.114-122ArticlesСтатьиResearch ArticleAlirocumab in patients of very high cardiovascular riskПрименение алирокумаба у пациентов очень высокого сердечно-сосудистого рискаBoevaOlga I.БоеваОльга Игоревна

MD, PhD, DMSci., professor of the Department of therapy, cardiology and functional diagnostics with the course of nephrology

д.м.н., доцент, профессор кафедры терапии, кардиологии и функциональной диагностики с курсом нефрологии

box0271@mail.ruKokorinValentin A.КокоринВалентин Александрович

MD, PhD, DMSci., professor of the Department of hospital therapy

д.м.н., доцент, профессор кафедры госпитальной терапии

valentinkokorin@yahoo.comCentral State Medical Academy of the Presidential Executive OfficeФГБОУ ДПО «Центральная государственная медицинская академия» УД Президента РФN.I. Pirogov Russian National Research Medical UniversityФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России1501202281VOL 8, NO1 (2022)ТОМ 8, №1 (2022)11412226022023Copyright ©; 2022, Bionika MediaCopyright ©; 2022, ООО «Бионика Медиа»2022Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2412-4036/article/view/288769

In the present review, the focus is on the rationale for proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors in the dyslipidemia correction in patients with very high and extreme cardiovascular risk.

В фокусе внимания этой обзорной работы - обоснование применения ингибиторов пропротеиновой конвертазы субтилизина/кексина типа 9 (PCSK9) в коррекции дислипидемии с акцентом на категории больных очень высокого и экстремального сердечно-сосудистого риска.

dyslipidemiahigh cardiovascular risklipid-lowering therapyPCSK9 inhibitorsalirocumabдислипидемиявысокий сердечно-сосудистый рискгиполипидемическая терапияингибиторы PCSK9алирокумабAwan Z., Seidah N.G., MacFadyen J.G. et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem. 2012; 58(1): 183-89. doi: 10.1373/clinchem.2011.172932.Welder G., Zineh I., Pacanowski M.A. et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res. 2010; 51(9): 2714-21. doi: 10.1194/jlr.M008144.Stein E.A., Mellis S., Yancopoulos G.D. et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012; 366(12): 1108-18. doi: 10.1056/NEJMoa1105803.Dias C.S., Shaywitz A.J., Wasserman S.M. et al. Effects of AMG145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol. 2012; 60(19): 1888-98. doi: 10.1016/j.jacc.2012.08.986.ClinicalTrials.gov. The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2) [Internet]. Available at: https://clinicaltrials.gov/ct2/show/NCT01975389 (cited 2013 October 21).Norata G.D., Tibolla G., Catapano A.L. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol. 2014; 54: 273-93. doi: 10.1146/annurev-pharmtox-011613-140025.Abifadel M., Varret M., Rabes J.-P. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34(2): 154-56. doi: 10.1038/ng1161.41.Shimada Y.J., Cannon C.P. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. Eur Heart J. 2015; 36(36): 2415-24. doi: 10.1093/eurheartj/ehv174.Кухарчук В.В., Ежов М.В., Сергиенко И.В. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020; 1: 7-42Mach F., Baigent C., Catapano A.L. et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111-88. doi: 10.1093/eurheartj/ehz455.Schmidt A.F., Carter J.-P.L., Pearce L.S. et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020; 10(10): CD011748. doi: 10.1002/14651858.CD011748.pub3.Ference B.A., Ginsberg H.N., Graham I. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32): 2459-72. doi: 10.1093/eurheartj/ehx144.Catapano A.L., Graham I., De Backer G. et al. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2016; 37(39): 2999-3058. doi: 10.1093/eurheartj/ehw272.McKenney J.M., Koren M.J., Kereiakes D.J. et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012; 59(25): 2344-53. doi: 10.1016/j.jacc.201 2.03.007.Schwartz G.G., Bessac L., Berdan L.G. et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014; 168(5): 682-89. doi: 10.1016/j.ahj.2014.07.028.Landmesser U., Chapman M.J., Stock J.K. et al. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2018; 39(14): 1131-43. doi: 10.1093/eurheartj/ehx549.Stein E.A., Gipe D., Bergeron J. et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012; 380(9836): 29-36. doi: 10.1016/S0140-6736(12)60771-5.Teramoto T., Kobayashi M., Uno K. et al. Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies). Am J Cardiol. 2016; 118(1): 56-63. doi: 10.1016/j.amjcard.2016.04.011.Инструкция по медицинскому применению лекарственного препарата Пралуэнт, раствор для подкожного введения, 75 или 150 мг/мл. РУ № ЛП-004078 (АО «Санофи-Авентис Груп», Франция). Доступ: https://grls.rosminzdrav.ru/Grls_View_v2_aspx?routingGuid=72fb3609-34cf-40e6-b158-50d388a4d0d8&t= (дата обращения - 01.09.2021).Greig S.L., Deeks E.D. Alirocumab: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2016; 16(2): 141-52. doi: 10.1007/s40256-016-0166-3.Tsimikas S., Fazio S., Ferdinand K.C. et al. NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol. 2018; 71(2): 177-92. doi: 10.1016/j.jacc.2017.11.014.Cannon C.P., Braunwald E., McCabe C.H. et al.Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350(15): 1495-504. doi: 10.1056/NEJMoa040583.Wiviott S.D., Cannon C.P., Morrow D.A. et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005; 46(8): 1411-16. doi: 10.1016/j.jacc.2005.04.064.Szarek M., White H.D., Schwartz G.G. Alirocumab reduces total nonfatal cardiovascular and fatal events: The ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019; 73(4): 387-96. doi: 10.1016/j.jacc.2018.10.039.Steg P.G., Szarek M., Bhatt D.L. et al. Effect of alirocumab on mortality after acute coronary syndromes. Circulation. 2019; 140(2): 103-12. doi: 10.1161/CIRCULATIONAHA.118.038840.Kearney P.M., Blackwell L., Collins R. et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008; 371(9607): 117-25. doi: 10.1016/S0140-6736(08)60104-X.Ginsberg H.N., Elam M.B., Lovato L.C. et al. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17): 1563-74. doi: 10.1056/NEJMoa1001282.Boekholdt S.M., Hovingh G.K., Mora S. et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a metaanalysis of statin trials. J Am Coll Cardiol. 2014; 64(5): 485-94. doi: 10.1016/j.jacc.2014.02.615.Cannon C.P., Blazing M.A., Giugliano R.P. et al. IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372(25): 2387-97. doi: 10.1056/NEJMoa1410489.Keech A., Simes R.J., Barter P. et al. Field Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366(9500): 1849-61. doi: 10.1016/S0140-6736(05)67667-2.Roth E.M., Taskinen M.R., Ginsberg H.N. et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial.Int J Cardiol. 2014; 176(1): 55-61. doi: 10.1016/j.ijcard.2014.06.049.Moriarty P.M., Thompson P.D., Cannon C.P. et al. Efficacy and safety of alirocumab versus ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015; 9(6): 758-69. doi: 10.1016/j.jacl.201 5.08.006.Stroes E., Guyton J.R., Farnier M. et al. for the ODYSSEY CHOICE II investigators. Efficacy and safety of alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study. J Am Heart Assoc. 2016; 5(9): e003421. doi: 10.1161/JAHA.116.003421.Kastelein J.J., Ginsberg H.N., Langslet G. et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolemia. Eur Heart J. 2015; 36(43): 2996-3003. doi: 10.1093/eurheartj/ehv370.Ginsberg H.N., Rader D.J., Raal F.J. et al. Efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia. Cardiovasc Drugs Ther. 2016; 30(5): 473-83. doi: 10.1007/s10557-016-6685-y.Schwartz G.G., Steg P.G., Szarek M. et al. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018; 379(22): 2097-107. doi: 10.1056/NEJMoa1801174.Jernberg T., Hasvold P., Henriksson M. et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015; 36(19): 1163-70. doi: 10.1093/eurheartj/ehu505.Zhao S., Wang Y., Mu Y. et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS). Atherosclerosis. 2014; 235(2): 463-69. doi: 10.1016/j.atherosclerosis.2014.05.916.Reiner Z., De Backer G., Fras Z. et al. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries - findings from the EUROASPIRE IV survey. Atherosclerosis. 2016; 246: 243-50. doi: 10.1016/j.atherosclerosis.2016.01.018.De Backer G., Jankowski P., Kotseva K. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019; 285: 135-46. doi: 10.1016/j.atherosclerosis.2019.03.014Gitt A.K., Drexel H., Feely J. et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prevent Cardiol. 2012; 19(2): 221-30. doi: 10.1177/1741826711400545.Benn M., Watts G.F., Tybjaerg-Hansen A. et al. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab. 2012; 97(11): 3956-64. doi: 10.1210/jc.2012-1563.Nanchen D., Gencer B., Auer R. et al. Prevalence and management of familial hypercholesterolemia in patients with acute coronary syndromes. Eur Heart J. 2015; 36(36): 2438-45. doi: 10.1093/eu-rheartj/ehv289.Ежов М.В., Лазарева Н.В., Сагайдак О.В. с соавт. Частота нарушений липидного обмена и применение статинов при остром коронарном синдроме (по данным Федерального Регистра острого коронарного синдрома). Атеросклероз и дислипиде-мии. 2018; 1: 47-57.Россия в цифрах - 2019. Краткий статистический сборник. М.: Росстат. 2019. [Russia in Figures 2019. Brief statistical book. Moscow: Rosstat. 2019 (In Russ.)].Nordestgaard B.G., Chapman M.J., Humphries S.E. et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013; 34(45): 3478-3490a. doi: 10.1093/eurheartj/eht273.Дедов И.И., Александров A.A. Проблемы острого инфаркта миокарда у больных сахарным диабетом. Сахарный диабет. 2008; 1: 4-10.Какорин С.В., Тулякова Э.В., Воронкова К.В., Мкртумян А.М. Острое нарушение мозгового кровообращения у больных сахарным диабетом 2 типа. Сахарный диабет. 2013; 1: 63-70Sarwar N., Gao P., Seshasai S.R. et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375(9733): 2215-22. doi: 10.1016/S0140-6736(10)60484-9.Simpson S.H., Lin M., Eurich D.T.Community pharmacy-based inducement programs associated with better medication adherence: a cohort study. Ann Pharmacother. 2017; 51(8): 630-39. doi: 10.1177/1060028017703720.Голухова Е.З., Кузнецова Е.В. Реваскуляризация миокарда у больных ИБС в сочетании с сахарным диабетом 2-го типа: обзор современных технологий. Сахарный диабет. 2016; 5: 406-13Ярбеков Р.Р., Чигогидзе Н.А., Сигаев И.Ю., Керен М.А. Ближайшая и отдаленная эффективность чрескожного коронарного вмешательства у больных ИБС с многососудистым поражением коронарных артерий и сахарным диабетом II типа. Анналы хирургии. 2014; 5: 21-26Толпыгина С.Н., Марцевич С.Ю. Изучение динамики частоты приема основных классов лекарственных препаратов, показанных при лечении пациентов с хронической ишемической болезнью сердца, с 2004 по 2014 г. данные регистра прогноз ИБС. Клиницист. 2016; 1: 29-35Vonbank A., Agewall S., Kjeldsen K.P. et al.Comprehensive efforts to increase adherence to statin therapy. Eur Heart J. 2017; 38(32): 2473-79. doi: 10.1093/eurheartj/ehw628.Krempf M., Simpson R.J., Ramey D.R. et al. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. Lipids Health Dis. 2015; 14(1): 45-47. doi: 10.1186/s12944-015-0037-y.Недогода С.В., Чумачек Е.В., Саласюк А.С. Обоснование применения алирокумаба при остром коронарном синдроме с клинико-экономической точки зрения. Клиническая фармакология и терапия. 2019; 2: 99-104Зырянов С.К., Дьяков И.Н. Прогнозный экономический эффект применения алирокумаба у пациентов с гиперхолестеринемией и высоким сердечно-сосудистым риском. Клиническая фармакология и терапия. 2018; 1: 90-96